Immuneering presents lung cancer data as Mizuho keeps Buy for Immuneering stock

Published on 10/16/2026 at 03:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter loss reached USD 0.27 per share against USD 0.26 consensus. Immuneering stock stands at USD 235.5 million market value before November 11 results.

Clinical milestones and valuation

Immuneering announced its lung cancer poster on October 2, 2026.
The ESMO pancreatic cancer poster is scheduled for October 25, 2026.
Immuneering had a USD 235.5 million market capitalization on October 15, 2026.

IMRX, US45254E1073, Illustration mit AI erstellt.

Immuneering announced lung cancer poster data on October 2, 2026, while Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating and set a USD 12.00 price target, according to Yahoo Finance and Markets Insider. The poster is intended to support a planned Phase 2 study combining atebimetinib with PD-1 checkpoint blockade in lung cancer patients.

Clinical milestones carry the story

Immuneering is developing atebimetinib as an oral MEK inhibitor for cancers driven by RAS, RAF and other MAPK alterations. The October 2 release described preclinical evidence in RAS-mutant tumor models and identified November 6, 2026, as the presentation date at the Society for Immunotherapy of Cancer meeting, according to Yahoo Finance.

The chronology shows a rapid sequence of development updates. On August 5, 2026, Immuneering reported a second-quarter adjusted loss of USD 0.27 per share versus a USD 0.26 consensus estimate, according to MarketBeat. On September 24, 2026, the company announced an ESMO poster for its Phase 3 MAPKeeper 301 pancreatic cancer trial, and on October 2 it announced the SITC lung cancer poster, according to Immuneering.

What dates shape the next catalyst?

The ESMO poster is scheduled for October 25, 2026, and the full abstract is due for publication on October 19, 2026, according to Immuneering. The SITC presentation follows on November 6, 2026. MarketBeat lists November 11, 2026, as the estimated date for the third-quarter report and gives a consensus loss estimate of USD 0.29 per share, compared with USD 0.38 per share in the year-earlier quarter.

Valuation reflects development risk

Immuneering had a market capitalization of USD 235.5 million on October 15, 2026. Its 52-week range was USD 3.38 to USD 8.48, while the average analyst target reported by MarketBeat was USD 15.71 on October 9, 2026. Those figures place the clinical milestones alongside a company still funding late-stage research and reporting quarterly losses.

Nasdaq quote stays below its yearly high

The stock was last at USD 3.64 on Nasdaq on October 15, 2026, at 4:00 p.m. ET. The next scheduled checkpoints are the ESMO poster on October 25, 2026, and the estimated third-quarter report on November 11, 2026.